Irvine, California-based Agendia received a CE Mark for its next-generation sequencing-based MammaPrint BluePrint breast cancer recurrence and molecular subtyping kit.

MammaPrint analyzes 70 genes most connected with breast cancer recurrence to determine a low or high risk of cancer recurrence result, while BluePrint analyzes 80 genes which classify a patient’s breast cancer into functional molecular subtypes.

The device can aid physicians in personalizing treatment management for patients by identifying early-stage breast cancer in women that is at a genomic low or high risk for distant metastasis within five years.